TNF Pharma closes $7M private placement at 44% premium; closes LPU acquisition

Q/C TECHNOLOGIES, INC.

Closed $7M private placement of 7,000 Series H preferred shares convertible to 1.4M common at $5.00/share, plus warrants for 1.4M shares at $5.00.
Conversion/exercise limited pending stockholder approval; placement agents include Rodman & Renshaw, H.C. Wainwright, and GPN.
Closed acquisition of LPU Holdings LLC, issuing Series I preferred stock convertible into 747,362 common shares.
Extended maturity of Series F and F-1 preferred stock to March 2, 2027 and removed amortization payments.
Common shares outstanding: 1,846,930 as of September 3, 2025; company plans to fund blockchain accelerator development.

item 1.01 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.